The primary objective of this study is to assess the efficacy and safety of an
extended-release (ER) formulation of pramipexole in comparison with placebo for the treatment
of fibromyalgia.
The objective of the open-label phase is to assess the safety profile and effect of
Pramipexole (PPX) extended-release (ER) in fibromyalgia patients over a 24-week period.